Completed PHASE3 INTERVENTIONAL 3-arm NCT00250679

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease

Sponsor: Sumitomo Pharma America, Inc.

Conditions Bronchitis Chronic Obstructive Pulmonary Disease Emphysema

Interventions Arformoterol 25 ųg BID Arformoterol tartrate inhalation solution Formoterol 12 ųg BID Placebo

Updated 9 times since 2017 Last updated: May 29, 2012 Started: Oct 31, 2005 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00250679, this PHASE3 trial focuses on Bronchitis and Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by Sumitomo Pharma America, Inc., it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2021 — Sep 2023 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma America, Inc.

Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Bay Pines, United States , Birmingham, United States , Brandon, United States , Carmichael, United States , Chapel Hill, United States , Charleston, United States and 49 more locations